Studies on uterine contractility following mifepristone and various routes of misoprostol

Contraception

Volumn 74, Issue 1, 2006, Pages 31-35

  Gemzell Danielsson, Kristina ^a   Bygdeman, Marc ^a   Aronsson, Annette ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Medical abortion; Mifepristone; Misoprostol; Sublingual administration; Uterine contractility

Indexed keywords

MIFEPRISTONE; MISOPROSTOL; PROSTAGLANDIN DERIVATIVE;

CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; MYOMETRIUM; REVIEW; SLOW RELEASE FORMULATION; STOMACH ULCER; SYSTEMATIC REVIEW; TABLET FORMULATION; THERAPEUTIC ABORTION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX; UTERUS CONTRACTILITY;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ABORTIFACIENT AGENTS, STEROIDAL; ABORTION, INDUCED; ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, ORAL; ADMINISTRATION, SUBLINGUAL; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MIFEPRISTONE; MISOPROSTOL; PREGNANCY; TIME FACTORS; UTERINE CONTRACTION;

EID: 33744979988     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.03.009     Document Type: Review

References (33)

1. Csapo A.I., Pulkkinen M.O., and Wiest W.G. Effects of luteectomy and progesterone replacement therapy in early pregnant patients. Am J Obstet Gynecol 115 (1973) 759-765
2. Csapo A.I. Prostaglandin impact inverted question mark for menstrual induction. Popul Rep G 4 (1974) 33-40
3. Swahn M.L., and Bygdeman M. Medical methods to terminate early pregnancy. In: Bygdeman M. (Ed). Baillière's clinical obstetrics and gynecology Vol. 4 (2) (1990), Baillière Tindall, London 293-306
4. Herrman W., Wyss R., Riondel A., et al. Effect d'un steroid anti-progesteron chez la femme; interruption du cycle menstruel et de la grossess au debut. C R Acad Sci (Paris) 294 (1982) 933-939
5. Kovacs L., Sas M., Resch B.A., et al. Termination of early pregnancy by RU 486 - an antiprogestional compound. Contraception 29 (1984) 399-410
6. Van Look P.F.A., and Bygdeman M. Antiprogestational steroids: a new dimension in human fertility regulation. In: Mulligan S.R. (Ed). Oxford reviews of reproductive biology (1989), Oxford, England 1-60
7. Bygdeman M., and Swahn M.L. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception 32 (1985) 45-51
8. Swahn M.L., and Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynaecol 95 (1988) 126-134
9. Garfield R.E., and Blennerhasset Miller S.M. Control of myometrial contractility: role and regulation of gap junctions. Oxf Rev Reprod Biol 10 (1988) 436-490
10. Norman J.E., Thong K.J., and Baird D.T. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 338 (1991) 1233-1236
11. Cameron I.T., Michie A.F., and Baird D.T. Therapeutic abortion in early pregnancy with antiprogestogen RU 486 alone or in combination with a prostaglandin analogue (gemeprost). Contraception 34 (1986) 459-468
12. Ulmann A., Silvestre L., Chenama L., et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Acta Obstet Gynecol Scand 71 (1992) 278-283
13. UK Multicentre Trial. The efficacy and tolerance of mifepristone and prostaglandin in first trimester of pregnancy. Br J Obstet Gynaecol 97 (1990) 480-486
14. World Health Organization. Termination of pregnancy with reduced doses of mifepristone. Br Med J 307 (1993) 532-537
15. Norman J.E., Kelly R.W., and Baird D.T. Uterine activity and decidual prostaglandin production in women in early pregnancy in response to mifepristone with or without indomethacin in vivo. Hum Reprod 6 (1991) 740-744
16. Peyron R., Aubény E., Targosz V., et al. Early pregnancy interruption with RU 486 (mifepristone) and misoprostol, an orally active prostaglandin analogue. N Engl J Med 328 (1993) 1509-1513
17. El-Refaey H., Rajasekar D., Abdotta M., et al. Induction of abortion with mifepristone (RU 486) and oral and vaginal misoprostol. N Engl J Med 332 (1995) 983-987
18. McKinley C., Joo Thong K., and Baird D.T. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod 8 (1993) 1502-1505
19. von Hertzen H., Honkanen H., Piaggio G., et al. WHO Research Group on Post-Ovulatory Methods for Fertility Regulation. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. Part 1: efficacy. BJOG 110 (2003) 808-818
20. Zieman M., Fong S.K., Benowitz N.L., et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol 90 (1997) 88-92
21. Tang O.S., Schweer H., Seyberth H.W., et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 17 (2002) 332-336
22. Gemzell-Danielsson K., Marions L., Rodriguez A., et al. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol 93 (1999) 275-280
23. Caldeyro-Barcia R., and Poserro J.J. Oxytocin and contractility of the human pregnant uterus. Ann N Y Acad Sci 75 (1959) 813-830
24. Ho P.C., Ngai S.W., Liu K.L., et al. Vaginal misoprostol compared with oral misoprostol in termination of second trimester pregnancy. Obstet Gynecol 90 (1997) 735-738
25. Tang O.S., and Ho P.C. Pilot study on the use of sublingual misoprostol for medical abortion. Contraception 64 (2001) 315-317
26. Aronsson A., Bygdeman M., and Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum Reprod 19 (2004) 81-84
27. Tang O.S., Lau W.N., Chan C.C., and Ho P.C. A prospective randomised comparison of sublingual and vaginal misoprostol in second trimester termination of pregnancy. BJOG 111 (2004) 1001-1005
28. Schaff E.A., Fielding S.L., Westhoff C., et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA 284 (2000) 1948-1953
29. Creinin M.D., Fox M.C., Teal S., et al. MOD Study Trial Group. A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion. Obstet Gynecol 103 5 Pt 1 (2004) 851-859
30. Winikoff B. Acceptability of medical abortion in early pregnancy. Fam Plann Perspect 185 (1995) 142-148
31. Bygdeman M., Christensen N.J., Dimov V., et al. Termination of pregnancy by a slow release device containing 16, 16-dimethyl-trans-delta 2 PGE1 methyl ester. Asia Oceania J Obstet Gynaecol 10 (1984) 359-365
32. Cameron I.T., and Baird D.T. A controlled release form of 16,16-dimethyl-trans-delta 2-PGE, methyl ester for early abortion. Contraception 33 (1986) 121-125
33. Fiala C., Aronsson A., Stephansson O., Hellborg M., and Gemzell-Danielsson K. Effects of slow release misoprostol on uterine contractility in early pregnancy. Hum Reprod 20 (2005) 2648-2652 [Electronic publication, 2005 May 26]